Technical Analysis for TRIL - Trillium Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 0.3001 -1.61% 0.00
TRIL closed down 1.61 percent on Friday, November 22, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical TRIL trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Centerline Cross Bullish -1.61%
Calm After Storm Range Contraction -1.61%
Upper Bollinger Band Walk Strength -1.61%
Inside Day Range Contraction -1.61%

Older signals for TRIL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. For more information visit: www.trilliumtherapeutics.com
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Tumor Cancer Immunotherapy Acute Myeloid Leukemia Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47
Is TRIL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.2
52 Week Low 0.24
Average Volume 216,640
200-Day Moving Average 0.4657
50-Day Moving Average 0.3003
20-Day Moving Average 0.2762
10-Day Moving Average 0.2842
Average True Range 0.0279
ADX 18.22
+DI 18.2028
-DI 14.018
Chandelier Exit (Long, 3 ATRs ) 0.2553
Chandelier Exit (Short, 3 ATRs ) 0.3242
Upper Bollinger Band 0.3105
Lower Bollinger Band 0.2419
Percent B (%b) 0.85
BandWidth 24.837075
MACD Line 0.0021
MACD Signal Line -0.004
MACD Histogram 0.0061
Fundamentals Value
Market Cap 3.24 Million
Num Shares 10.8 Million
EPS -4.08
Price-to-Earnings (P/E) Ratio -0.07
Price-to-Sales 0.00
Price-to-Book 4.22
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.36
Resistance 3 (R3) 0.37 0.35 0.35
Resistance 2 (R2) 0.35 0.33 0.35 0.35
Resistance 1 (R1) 0.32 0.32 0.32 0.32 0.35
Pivot Point 0.31 0.31 0.30 0.31 0.31
Support 1 (S1) 0.28 0.29 0.27 0.28 0.26
Support 2 (S2) 0.27 0.28 0.26 0.25
Support 3 (S3) 0.24 0.27 0.25
Support 4 (S4) 0.24